Marketed unapproved drugs workshop
Executive Summary
A public workshop for businesses marketing unapproved drugs will be hosted by FDA Jan. 9. FDA will provide clarification and direction to companies on how to seek drug approval; topics slated for the meeting include NDAs, ANDAs, OTC monographs, application processes, user fees and market exclusivity. The agency is convening the meeting because many companies sought clarification following the June 2006 publication of the agency's Marketed Unapproved Drugs-Compliance Policy Guide (1"The Pink Sheet" June 12, 2006, p. 10)...
You may also be interested in...
FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions
FDA is encouraging manufacturers of marketed but unapproved drugs to voluntarily submit applications by highlighting the possibility of a de facto exclusivity period for sponsors who receive NDA approval for a drug that other firms are marketing without approval
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.